Type
|
Public |
---|---|
Traded as | NASDAQ: HBIO |
Industry | Life Science |
Founded | 1901 |
Headquarters | 84 October Hill Road Holliston, MA 01746, United States |
Revenue | $104.521 million |
Website | http://www.harvardbioscience.com/ |
Harvard Bioscience, Inc. is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research.
Headquartered in Holliston, Massachusetts, United States, the company has 20 wholly owned subsidiaries. Brands include: AHN Biotechnologie, Biochrom, BioDrop, BTX, CMA, Coulbourn Instruments, Denville Scientific, Harvard Apparatus, HEKA, Hoefer, Hugo Sachs Elektronik, Multichannel Systems, Panlab, Scie-Plas, and Warner Instruments.
Harvard Bioscience was founded in 1901. Frustrated by the poor quality of equipment then available, Dr. William T. Porter began manufacturing his own high quality physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day. His equipment gained an enviable reputation for quality and reliability and began to be known simply as the Harvard Apparatus.
In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering in December 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.
Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.
The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%. On November 13, 2013, Harvard Bioscience Inc. announced its allocation of tax basis for spin-off of Harvard Apparatus Regenerative Technology.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-01 | Future report Set alerts | |
Q2 2022 | 2022-08-04 | 0.05 | 0.05 |
Q1 2022 | 2022-05-04 | 0.04 | 0.04 |
Q4 2021 | 2022-03-08 | 0.08 | 0.08 |
Q3 2021 | 2021-11-03 | 0.06 | 0.06 |
Q2 2021 | 2021-08-05 | 0.06 | 0.06 |
Q1 2021 | 2021-05-06 | 0.05 | 0.05 |
Q4 2020 | 2021-03-10 | 0.08 | 0.08 |
Q3 2020 | 2020-11-05 | 0.04 | 0.04 |
Q2 2020 | 2020-08-05 | 0.05 | 0.05 |
2015-10-30 | Lower Price Target | Benchmark Co. | Buy | $8.00 to $6.00 |
2015-07-28 | Initiated Coverage | Benchmark Co. | Buy | $8.00 |
2014-07-24 | Initiated Coverage | Alere Financial | Buy | $8.00 |
2014-06-25 | Initiated Coverage | Janney Montgomery Scott | Buy to Buy | $9.00 |
2013-11-26 | Upgrade | Sidoti | Neutral to Buy |
2015-10-30 | Lower Price Target | Benchmark Co. | Buy | $8.00 to $6.00 |
2015-07-28 | Initiated Coverage | Benchmark Co. | Buy | $8.00 |
2014-07-24 | Initiated Coverage | Alere Financial | Buy | $8.00 |
2014-06-25 | Initiated Coverage | Janney Montgomery Scott | Buy to Buy | $9.00 |
2013-11-26 | Upgrade | Sidoti | Neutral to Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In HBIO 65 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Harvey Partners, LLC | 2.91M |
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. | 2.72M |
DIMENSIONAL FUND ADVISORS LP | 1.74M |
Vanguard Group, Inc | 1.54M |
ROYCE & ASSOCIATES LLC | 1.50M |
GRANAHAN INVESTMENT MANAGEMENT INC/MA | 1.49M |
Portolan Capital Management, LLC | 1.34M |
BlackRock Inc. | 1.19M |
BlackRock Institutional Trust Company, N.A. | 1.16M |
ACADIAN ASSET MANAGEMENT LLC | 1.08M |
HEARTLAND ADVISORS INC | 1.05M |
Archon Capital Management LLC | 0.88M |
RENAISSANCE TECHNOLOGIES LLC | 0.85M |
Monarch Partners Asset Management LLC | 0.80M |
GEODE CAPITAL MANAGEMENT, LLC | 0.34M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
GRAZIANO CHANE Chief Executive Officer | 9.30% (3005150) | HART / HBIO / |
GREEN DAVID President | 2.87% (925571) | HART / HBIO / |
Duchemin Jeffrey Chief Executive Officer | 1.99% (641854) | HBIO / |
LEWIS EARL R | 1.48% (477050) | ADGE / FLIR / HBIO / NXTM / |
LUSCINSKI SUSAN M Chief Operating Officer | 1.45% (469720) | HBIO / |
Gagnon Robert E. Chief Financial Officer | 1.11% (357938) | HBIO / |
KENNEDY JOHN F | 0.90% (291630) | HART / HBIO / |
Sun Yong VP - Strategic Marketing | 0.63% (204858) | HBIO / |
McNaughton Thomas Chief Financial Officer | 0.53% (171613) | HART / HBIO / |
UVEGES GEORGE | 0.44% (142685) | HBIO / |
Green James W | 0.43% (139212) | ALOG / HBIO / |
LOY BERTRAND | 0.36% (117750) | BTUI / ENTG / HBIO / |
HARTE NEAL J | 0.33% (106399) | HBIO / |
DISHMAN ROBERT A | 0.16% (51055) | HBIO / |
Sibony Yoav VP - Global Sales | 0.07% (21582) | HBIO / |
Loewald Thomas W | 0.04% (13700) | HBIO / TMO / |
Eade Katherine A. | 0.04% (13400) | HBIO / |